Shu Huang1, Seonkyeong Yang1, Shirly Ly2, Ryan H Yoo3, Wei-Hsuan Lo-Ciganic1,4, Michael T Eadon5, Titus Schleyer5,6, Elizabeth Whipple7, Khoa Anh Nguyen8. 1. Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA. 2. Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, PO Box 100496, Gainesville, FL, USA. 3. Fenix Group International, LLC, Pompano Beach, FL, USA. 4. Center for Drug Evaluation and Safety, College of Pharmacy, University of Florida, Gainesville, FL, USA. 5. Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. 6. Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN, USA. 7. Ruth Lilly Medical Library, Indiana University School of Medicine, Indianapolis, IN, USA. 8. Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, PO Box 100496, Gainesville, FL, USA. khoanguyen@cop.ufl.edu.
Abstract
PURPOSE: To conduct a systematic review to identify studies that assessed the association between CYP2C19 polymorphisms and clinical outcomes in peripheral artery disease (PAD) patients who took clopidogrel. METHODS: We systematically searched Ovid EMBASE, PubMed, and Web of Science from November 1997 (inception) to September 2020. We included observational studies evaluating how CYP2C19 polymorphism is associated with clopidogrel's effectiveness and safety among patients with PAD. We extracted relevant information details from eligible studies (e.g., study type, patient population, study outcomes). We used the Risk of Bias in Non-randomized Studies-of Interventions (ROBINS-I) Tool to assess the risk of bias for included observational studies. RESULTS: The outcomes of interest were the effectiveness and safety of clopidogrel. The effectiveness outcomes included clinical ineffectiveness (e.g., restenosis). The safety outcomes included bleeding and death related to the use of clopidogrel. We identified four observational studies with a sample size ranging from 50 to 278. Outcomes and comparison groups of the studies varied. Three studies (75%) had an overall low risk of bias. All included studies demonstrated that carrying CYP2C19 loss of function (LOF) alleles was significantly associated with reduced clinical effectiveness and safety of clopidogrel. CONCLUSIONS: Our systematic review showed an association between CYP2C19 LOF alleles and reduced functions of clopidogrel. The use of CYP2C19 testing in PAD patients prescribed clopidogrel may help improve the clinical outcomes. However, based on the limited evidence, there is a need for randomized clinical trials in PAD patients to test both the effectiveness and safety outcomes of clopidogrel.
PURPOSE: To conduct a systematic review to identify studies that assessed the association between CYP2C19 polymorphisms and clinical outcomes in peripheral artery disease (PAD) patients who took clopidogrel. METHODS: We systematically searched Ovid EMBASE, PubMed, and Web of Science from November 1997 (inception) to September 2020. We included observational studies evaluating how CYP2C19 polymorphism is associated with clopidogrel's effectiveness and safety among patients with PAD. We extracted relevant information details from eligible studies (e.g., study type, patient population, study outcomes). We used the Risk of Bias in Non-randomized Studies-of Interventions (ROBINS-I) Tool to assess the risk of bias for included observational studies. RESULTS: The outcomes of interest were the effectiveness and safety of clopidogrel. The effectiveness outcomes included clinical ineffectiveness (e.g., restenosis). The safety outcomes included bleeding and death related to the use of clopidogrel. We identified four observational studies with a sample size ranging from 50 to 278. Outcomes and comparison groups of the studies varied. Three studies (75%) had an overall low risk of bias. All included studies demonstrated that carrying CYP2C19 loss of function (LOF) alleles was significantly associated with reduced clinical effectiveness and safety of clopidogrel. CONCLUSIONS: Our systematic review showed an association between CYP2C19 LOF alleles and reduced functions of clopidogrel. The use of CYP2C19 testing in PAD patients prescribed clopidogrel may help improve the clinical outcomes. However, based on the limited evidence, there is a need for randomized clinical trials in PAD patients to test both the effectiveness and safety outcomes of clopidogrel.
Authors: David Erlinge; Stefan James; Suman Duvvuru; Joseph A Jakubowski; Henrik Wagner; Christoph Varenhorst; Udaya S Tantry; Patricia B Brown; David Small; Brian A Moser; Scott S Sundseth; Joseph R Walker; Kenneth J Winters; Paul A Gurbel Journal: Thromb Haemost Date: 2014-01-09 Impact factor: 5.249
Authors: Victoria M Pratt; Andria L Del Tredici; Houda Hachad; Yuan Ji; Lisa V Kalman; Stuart A Scott; Karen E Weck Journal: J Mol Diagn Date: 2018-02-21 Impact factor: 5.568
Authors: Dirk Sibbing; Werner Koch; Daniela Gebhard; Tibor Schuster; Siegmund Braun; Julia Stegherr; Tanja Morath; Albert Schömig; Nicolas von Beckerath; Adnan Kastrati Journal: Circulation Date: 2010-01-18 Impact factor: 29.690
Authors: S A Scott; K Sangkuhl; C M Stein; J-S Hulot; J L Mega; D M Roden; T E Klein; M S Sabatine; J A Johnson; A R Shuldiner Journal: Clin Pharmacol Ther Date: 2013-05-22 Impact factor: 6.875
Authors: Brian Hutton; Georgia Salanti; Deborah M Caldwell; Anna Chaimani; Christopher H Schmid; Chris Cameron; John P A Ioannidis; Sharon Straus; Kristian Thorlund; Jeroen P Jansen; Cynthia Mulrow; Ferrán Catalá-López; Peter C Gøtzsche; Kay Dickersin; Isabelle Boutron; Douglas G Altman; David Moher Journal: Ann Intern Med Date: 2015-06-02 Impact factor: 25.391
Authors: Samuel G Johnson; Paul B Shaw; Thomas Delate; Deanna L Kurz; Dylon Gregg; John C Darnell; Christina L Aquilante Journal: Pharm Pract (Granada) Date: 2017-06-30
Authors: Khoa A Nguyen; Michael T Eadon; Ryan Yoo; Evan Milway; Allison Kenneally; Kevin Fekete; Hyun Oh; Khanh Duong; Elizabeth C Whipple; Titus K Schleyer Journal: Clin Transl Sci Date: 2020-12-05 Impact factor: 4.689